Mytos
Mytos is a London-based biotechnology company that has developed iDEM™, an automated cell manufacturing platform, and operates an automated CDMO service for clinical-stage cell therapy developers producing regenerative medicines, reducing batch costs by up to 50% versus manual manufacturing.
- Company typePrivate
- Founded2019
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Mytos does
Mytos is a UK-based biotechnology company that has developed iDEM™, an automated cell manufacturing platform designed to industrialize the production of regenerative medicines. The platform automates all unit operations in cell culture — coating, seeding, feeding, cell imaging, passaging, and harvesting — using the same 2D T-flash format as manual culture, which enables rapid protocol transfer without altering underlying biology. Mytos operates both a technology offering and a service offering: its automated CDMO (Contract Development and Manufacturing Organization) launched in October 2025 at CGT Catapult's 80,000 sqft Stevenage Manufacturing Innovation Centre, with stated capacity for up to 1,500 autologous doses or 25,000 allogeneic doses annually when clinical-ready in September 2026.
Mytos serves clinical-stage cell therapy developers across multiple therapeutic verticals — including Parkinson's, macular degeneration, hearing loss, bone regeneration, and heart failure — that face high manufacturing costs, operator-dependent batch failures, and difficulty scaling manual processes. Named partners include StemSight (ocular), Rinri Therapeutics (hearing loss), Novadip (bone regeneration), Aspen Neuroscience (Parkinson's), and Pluristyx (engineered iPSC lines). The company claims 10x labor reduction, 10x cleanroom footprint reduction, and up to 50% lower batch costs versus manual CDMOs, with no suite fees or device purchases required.
The business model combines CDMO services (managed services revenue per batch) with technology licensing potential, sold through B2B enterprise sales with dedicated product solutions and business development leadership. The CGT Catapult partnership provides embedded GMP and regulatory expertise. The company has raised over $24M cumulatively, including a $19M Series A in November 2023 led by Buckley Ventures, plus prior backing from Y Combinator, IQ Capital, Wing Venture Capital, Cur8 Capital, Pente Capital, and founders/executives of companies including Wayve, Dropbox, Segment, and Mercury.
Mytos firmographics
Firmographics- Name
- Mytos
- Legal name
- Mytos
- Website
- https://mytos.bio
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Mytos is a London-based biotechnology company that has developed iDEM™, an automated cell manufacturing platform, and operates an automated CDMO service for clinical-stage cell therapy developers producing regenerative medicines, reducing batch costs by up to 50% versus manual manufacturing.
- Ownership category
- akta.pro rank
Mytos industry classification
Industry- Product category
- Cell Therapy Contract Manufacturing (CDMO)
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Special Industry Machinery (No Metalworking Machinery) (3550)
- akta.pro primary industry
- Cell Therapy CDMO (HLAGABAD)
- akta.pro secondary industries
- Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG), Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC), Cell Therapy CDMO (Autologous/Allogeneic Manufacturing) (HLAGAGAA)
Keywords
Where Mytos is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Mytos business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
Revenue model
- CDMO Services: Contract Development and Manufacturing Organization services for regenerative medicine companies. Customers pay for manufacturing services including Process & Analytical Development and Regulatory Support. Revenue generated through batch production fees with cost-efficient automated manufacturing.
- Technology Licensing: iDEM platform made available to partners for automated cell manufacturing, enabling biotech companies to scale production of cell therapies from early clinical trials toward commercial-ready manufacturing.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Multi-year contract | CDMO manufacturing services with 50% cost reduction vs manual alternatives |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Mytos product offering
Product offeringCore offering
Mytos sells automated cell manufacturing services and licenses its proprietary iDEM™ automation platform to biotech and pharma companies developing regenerative cell therapies. Its core technology automates every unit operation in 2D T-flask cell culture — coating, seeding, feeding, imaging, passaging, and harvesting — within a closed system that delivers up to 10x reductions in labor and cleanroom footprint and ~50% lower batch costs than manual CDMOs. The company operates as an automated CDMO for stem-cell derived therapies (autologous and allogeneic, including iPSC-based products) and supports customers across process development, manufacturing, and regulatory activities.
Product overview
Mytos offers a unified platform combining its proprietary iDEM™ automation technology with integrated CDMO manufacturing services. The iDEM™ platform serves as the core technology that automates cell culture operations, while the Mytos CDMO service provides end-to-end manufacturing capabilities leveraging iDEM automation. The company also offers process and analytical development services along with regulatory support. Example applications include PSC expansion and cell banking, neural progenitor differentiation (for Parkinson's disease), cardiomyocyte differentiation (for heart failure), and RPE differentiation (for macular degeneration).
Differentiator
Problem solved
Functional benefit
Products and services
- iDEM™ (Intelligent Device for Automated Cell Manufacturing) Proprietary automated cell manufacturing platform that automates every unit operation in 2D T-flask cell culture — coating, seeding, feeding, cell imaging, passaging, and harvesting — within a closed system, enabling customers to port manual protocols to automation without altering biology and delivering up to 10x reductions in labor and cleanroom footprint.
- Mytos CDMO (Contract Development and Manufacturing Organization) Automated contract development and manufacturing service for regenerative cell therapies, covering process and analytical development, manufacturing, and regulatory support; delivers up to 50% lower batch costs than manual CDMOs with no suite fees or device purchases required.
Quantifiable outcome
- Reduces labour per batch by up to 10x compared to manual culture
- +3 more outcomes
Companies that use Mytos
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles2 records
Mytos technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature5 records
Mytos partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core.
- PluristyxcoreStrategic collaboration to automate manufacturing of Pluristyx's clinical-grade iPSC cell lines for regenerative medicine. Mytos provides iDEM automation platform and CDMO infrastructure while Pluristyx contributes engineered iPSC platform including iACT immune-cloaking and FailSafe safety-switch technologies.
- Cell and Gene Therapy Catapult (CGT Catapult)coreManufacturing partnership housing Mytos' first automated CDMO facility at CGT Catapult's 80,000 sqft Stevenage Manufacturing Innovation Centre. CGT Catapult provides GMP and regulatory expertise combined with Mytos' iDEM automation technology.
- StemSightcoreStrategic manufacturing collaboration to integrate Mytos' iDEM automated platform for ocular disease cell therapy applications. The partnership enables StemSight to scale production of cell therapies from early clinical trials toward commercial-ready manufacturing.
- Rinri TherapeuticscoreStrategic manufacturing collaboration to integrate iDEM platform for hearing loss treatment (neuronal precursor cells). Enables Rinri to scale production using automated manufacturing without changing the biology of their existing process.
- NovadipcoreStrategic manufacturing collaboration to integrate iDEM platform for bone regeneration therapy. Enables Novadip to increase output of existing facilities without delaying scaling to build out new capacity.
- Aspen NeurosciencecoreManufacturing collaboration where Aspen integrates Mytos' iDEM automated cell technology into its 22,000-square-foot facility for Parkinson's therapy. iDEM system enables Aspen to scale out for Phase 3 and ultimately commercialization, making more product at lower cost.
Scale indicators9 records
Recent moves8 records
Expansion highlights6 records
Mytos competitors and assessment
Company assessmentMarket position
Competitive moat6 records
Key highlights7 records
Customer concentration
Mytos social profiles
Digital presenceMytos financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mytos leadership team
Management profileNumber of profiles
Profiles10 records
Mytos funding detail
Funding detailFunding overview
Funding rounds3 records
Investors15 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mytos M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mytos
What does Mytos do?
Mytos sells automated cell manufacturing services and licenses its proprietary iDEM™ automation platform to biotech and pharma companies developing regenerative cell therapies. Its core technology automates every unit operation in 2D T-flask cell culture — coating, seeding, feeding, imaging, passaging, and harvesting — within a closed system that delivers up to 10x reductions in labor and cleanroom footprint and ~50% lower batch costs than manual CDMOs. The company operates as an automated CDMO for stem-cell derived therapies (autologous and allogeneic, including iPSC-based products) and supports customers across process development, manufacturing, and regulatory activities.
Is Mytos a public or private company?
Mytos is a private company. It is classified as venture growth investor backed and is currently operating.
When was Mytos founded?
Mytos was founded in 2019. It employs 11 to 50 people.
Where is Mytos based?
Mytos is headquartered in London, United Kingdom, in the Europe region.
How does Mytos make money?
Two revenue lines are on record. CDMO Services are the primary driver. The others are technology Licensing.
Does Mytos have an API?
No public API is recorded for Mytos.
What industry is Mytos in?
Mytos's product category is Cell Therapy Contract Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAD, Cell Therapy CDMO, with a secondary code of HLAAABAG, Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish). Its NAICS code is 3254 and its SIC code is 3550.